Study wrapper · #589
Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion.
Editor's note
In a mouse model of myocardial ischemia-reperfusion injury, researchers reported that hexarelin, a growth hormone secretagogue, was associated with improved left-ventricular function on MRI, less interstitial collagen and TGF-beta1, and reduced markers of inflammation (troponin-I, TNF-alpha) after 21 days, alongside a shift of autonomic balance toward parasympathetic tone. The proposed mechanism, vagal anti-inflammatory signaling, is consistent with the authors' earlier infarction work. This is one of many concordant rodent cardiac studies for hexarelin, which strengthens the preclinical mechanistic story but does not substitute for human evidence. The model is a single-species acute injury with modest numbers, and the authors' language about translational potential outruns the data. These are preclinical findings; human trials would be needed before any clinical conclusions.
Plain-language abstract
Researchers studied hexarelin, a lab-made peptide, in mice whose heart was injured by temporarily blocking then restoring blood flow in a coronary artery (ischemia-reperfusion injury). Mice received hexarelin or an inactive vehicle for 21 days starting just before blood flow was restored. Using MRI, the team found hexarelin-treated mice had better pumping function than untreated mice. Their hearts also showed less scar tissue and lower levels of inflammation and injury markers, and their nervous-system balance shifted toward the calming 'rest' branch. The authors suggest hexarelin protects the heart partly by activating anti-inflammatory nerve signals. The abstract reports no adverse events. These are preclinical findings in mice; human studies would be needed before drawing clinical conclusions.